Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication
Vinaixa C, Belli L, Berenguer M, Cortesi P, Strazzabosco M, Faccheti R, Rockenschaub S, Martini S, Morelli C, Donato F, Volpes R, Pasulo L, Pageaux G, Coilly A, Perricone G, Mazzarelli C, Di Nicola S, Berlakovich G, Duvuox C. Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication. Transplantation 2018, 102: s3. DOI: 10.1097/01.tp.0000542536.91165.49.Peer-Reviewed Original ResearchDirect acting antiviralsMedian Child-PughHepatocellular carcinomaChild-PughMedian followLiver transplantationMELD scoreClinical improvementSecond generation direct acting antiviralsClinical outcome 2 yearsDevelopment of HCCIntestine Transplant AssociationChronic HCV infectionLiver transplant candidatesLiver function testsStart of therapySignificant clinical improvementRisk of deathOutcomes 2 yearsDAA therapyEuropean LiverDecompensated cirrhosisHCV infectionAbdominal ultrasoundActing antiviralsThe optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level